findmyKOL
Clinical trialNCT03914794CompletedPhase 2Interventional

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

SponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrollment30Bladder CancerNMIBCNon-Muscle Invasive Bladder CancerUrothelial Carcinoma Recurrent
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Sibley Memorial Hospital

    Washington D.C., District of Columbia, United States

  • Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, United States

  • Associated Medical Professionals Urology

    Syracuse, New York, United States

  • Midlantic Urology

    Bala-Cynwyd, Pennsylvania, United States

  • Keystone Urology

    Lancaster, Pennsylvania, United States

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pemigatinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
2 Oct 2020
Primary completion
30 Sept 2025
Completion
30 Sept 2025
Last update posted
3 Oct 2025
Registered enrollment
30
Registry id
NCT03914794
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.